# Phase 1 lymphoma trials recruiting: 253 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 253 trials in phase 1 for lymphoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 lymphoma trials: 253 rows for $12.65, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 5 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/lymphoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 253
- Recruiting or not yet: 253
- Read on: November 19, 2026

## Trials

The 25 newest of 253, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07941531 | T-Cell Therapy Using CD7 Negative T-Cells Expressing CD7 CAR Expressed In Pediatric Patients With Hematological Malignancies. | St. Jude Children's Research Hospital | Phase 1 | Not yet recruiting | Lymphoma, AML, T-ALL, Hematologic Malignancy | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941531) |
| November 17, 2026 | NCT07941492 | A Trial of FHD-286 Plus Mosunetuzumab in Previously Treated Follicular Lymphoma | Weill Medical College of Cornell University | Phase 1 | Not yet recruiting | Follicular Lymphoma | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941492) |
| November 13, 2026 | NCT07936266 | Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R... | Sponsor not shown (see the record) | Phase 1 | Recruiting | B-cell Acute Lymphoblastic Leukemia (B-ALL) | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07936266) |
| November 10, 2026 | NCT07927816 | CD19 Sequential CD22 In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia | Sponsor not shown (see the record) | Phase 1 | Recruiting | Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia, In Vivo CAR-T, B-Cell Acute Lymphoblastic Leukemia | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07927816) |
| November 3, 2026 | NCT07914348 | Evaluation of LB-208 (HTR1B Antagonist) in Adult Patients With Relapsed or Refractory Solid Tumours and Lymphoma | Leukos Biotech S.L. | Phase 1 | Recruiting | Solid Tumor Malignancies, Lymphoma | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914348) |
| November 2, 2026 | NCT07910708 | GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia | Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital | Phase 1 | Recruiting | Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910708) |
| October 30, 2026 | NCT07906080 | Study to Evaluate the Feasibility and Safety of Autologous Cytokine-Induced Killer Cells (CIK\_D332) in Combination With Tafasitamab and... | Istituto Oncologico Veneto IRCCS | Phase 1 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906080) |
| October 26, 2026 | NCT07896213 | Metabolically Fit CD19 CAR T Cells With CD34 Selection Markers in Adults With CD19-Positive B-Cell Acute Lymphocytic Leukemia | Medical University of South Carolina | Phase 1 | Not yet recruiting | CD19 Positive, B-ALL, B-cell Acute Lymphocytic Leukemia, Chimeric Antigen Receptor T-cell, CAR-T Cell Therapy, MRD... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896213) |
| October 23, 2026 | NCT07891468 | huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers | University of Pennsylvania | Phase 1 | Not yet recruiting | Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Richter's Transformation | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07891468) |
| October 21, 2026 | NCT07887646 | A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in Adults With Diffuse Large B-cell... | BeOne Medicines | Phase 1 | Not yet recruiting | Diffuse Large B-Cell Lymphoma, B-cell Malignancies | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887646) |
| October 20, 2026 | NCT07883941 | Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid... | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies, Diffuse Large B Cell Lymphoma... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883941) |
| October 19, 2026 | NCT07881211 | A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in Adults With Diffuse Large B-cell... | BeOne Medicines | Phase 1 | Not yet recruiting | Diffuse Large B-Cell Lymphoma, B-Cell Malignancies | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881211) |
| October 13, 2026 | NCT07871747 | Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART) | University of Chicago | Phase 1 | Not yet recruiting | Lymphoma, B-Cell, Multiple Myeloma | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871747) |
| October 9, 2026 | NCT07869368 | BLinatumomab and iNKT in Relapsed B-Cell ALL | UNC Lineberger Comprehensive Cancer Center | Phase 1 | Not yet recruiting | B-Cell ALL, ALL (Acute B-Lymphoblastic Leukemia), Philadelphia Chromosome-Negative Lymphoblastic Leukemia... | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869368) |
| October 1, 2026 | NCT07853040 | A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment | Incyte Corporation | Phase 1 | Recruiting | Hepatic Insufficiency, Liver Diseases | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07853040) |
| September 28, 2026 | NCT07844967 | A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of HS-10506 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Hepatic Impairment (Moderate or Mild) & Normal Hepatic Function | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07844967) |
| September 25, 2026 | NCT07842445 | Phase 1a/1b Clinical Trials to Evaluate the Safety and Preliminary Efficacy of GNTbm-38. | Great Novel Therapeutics Biotech & Medicals Corporation | Phase 1 | Not yet recruiting | Solid Tumor (Phase I), Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07842445) |
| September 24, 2026 | NCT07838714 | Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic... | Ruijin Hospital | Phase 1 | Recruiting | B-cell Acute Lymphoblastic Leukemia | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07838714) |
| September 24, 2026 | NCT07838649 | Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity | Washington University School of Medicine | Phase 1 | Not yet recruiting | Lymphoma Cancer, Breast Cancer, Cancer of the Breast, Non-Hodgkin Lymphoma, Hodgkin Lymphoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07838649) |
| August 20, 2026 | NCT07775508 | In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma | Chinese PLA General Hospital | Phase 1 | Recruiting | B-cell Lymphoma | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07775508) |
| August 19, 2026 | NCT07774572 | Exploration of Circular RNA in B-cell Hematologic Malignancies | Ruijin Hospital | Phase 1 | Recruiting | Lymphoma, B-Cell Refractory | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07774572) |
| August 11, 2026 | NCT07758673 | Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell... | City of Hope Medical Center | Phase 1 | Recruiting | Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic... | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07758673) |
| July 27, 2026 | NCT07729397 | Autologous iC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma | The Methodist Hospital Research Institute | Phase 1 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), Anaplastic Large Cell... | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07729397) |
| July 24, 2026 | NCT07725406 | Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma | Weill Medical College of Cornell University | Phase 1 | Recruiting | Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM) | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07725406) |
| July 20, 2026 | NCT07714421 | Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients | Jonsson Comprehensive Cancer Center | Phase 1 | Not yet recruiting | Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, Primary Mediastinal Large... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07714421) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| City of Hope Medical Center | 11 |
| National Cancer Institute (NCI) | 8 |
| Institute of Hematology & Blood Diseases Hospital, China | 7 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 6 |
| Mayo Clinic | 5 |
| Ruijin Hospital | 5 |
| Baylor College of Medicine | 5 |
| M.D. Anderson Cancer Center | 4 |
| [Incyte Corporation](https://specstream.ai/data/clinical-trials/company/incyte-corporation) | 3 |
| Nurix Therapeutics, Inc. | 3 |
| Medical College of Wisconsin | 3 |
| Memorial Sloan Kettering Cancer Center | 3 |
| University of Pennsylvania | 3 |
| [Chongqing Precision Biotech Co., Ltd](https://specstream.ai/data/clinical-trials/company/chongqing-precision-biotech-co-ltd) | 3 |
| St. Jude Children's Research Hospital | 3 |
| Chinese PLA General Hospital | 3 |
| Abramson Cancer Center at Penn Medicine | 2 |
| Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. | 2 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 2 |
| Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | 2 |
| University of Utah | 2 |
| University of Colorado, Denver | 2 |
| [Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/hangzhou-zhongmei-huadong-pharmaceutical-co-ltd) | 2 |
| Peking University Cancer Hospital & Institute | 2 |
| [Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.](https://specstream.ai/data/clinical-trials/company/shanghai-fosun-pharmaceutical-industrial-development-co-ltd) | 2 |

## By country

| Country | Trials |
| --- | --- |
| United States | 133 |
| China | 85 |
| Australia | 16 |
| Spain | 15 |
| Italy | 11 |
| United Kingdom | 9 |
| France | 9 |
| Canada | 7 |
| Poland | 7 |
| Taiwan | 5 |
| South Korea | 5 |
| Germany | 5 |
| Denmark | 4 |
| Japan | 3 |
| Belgium | 2 |
| India | 2 |
| Serbia | 2 |
| Switzerland | 2 |
| Moldova | 2 |
| Ukraine | 2 |
| Bulgaria | 1 |
| Russia | 1 |
| Singapore | 1 |
| Turkey (Türkiye) | 1 |
| Netherlands | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Tex-Mex restaurants in the United States](https://specstream.ai/data/businesses/tex-mex-restaurants/united-states)
- [TV service providers in the United States](https://specstream.ai/data/businesses/tv-service-providers/united-states)
- [Water utilities in the United States](https://specstream.ai/data/businesses/water-utilities/united-states)
- [Adult education centers in the United States](https://specstream.ai/data/businesses/adult-education-centers/united-states)
- [Argentine restaurants in the United States](https://specstream.ai/data/businesses/argentine-restaurants/united-states)
- [B2B industrial and machine companies in the United States](https://specstream.ai/data/businesses/b2b-industrial-and-machine-companies/united-states)
